BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysacc…
Biotechnology
US, San Rafael [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 8.00 | 2.74 | 2.54 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -26.11 | 3.12 | 4.23 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 3.26 | 26.86 | 26.02 | |
| Cash | -7.36 | 5.54 | 5.98 | |
| Capex | -45.13 | -0.18 | -0.12 | |
| Free Cash Flow | -88.57 | 0.07 | 0.60 | |
| Revenue | 11.23 | 3.44 | 3.09 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -0.05 | 0.79 | 0.79 | |
| Operating Margin | 185.82 | 0.13 | 0.04 | |
| ROA | 115.92 | 0.01 | < 0.005 | |
| ROE | 111.92 | 0.02 | < 0.005 | |
| ROIC | 168.94 | 0.01 | < 0.005 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of BMRN is permitted for members.
5
Growth
The "Growth Entry" for the Focus of BMRN is permitted for members.
6
Leverage & Liquidity